<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: certain risks", fill: "#7b3f00"},
{source: "1: certain risks", target: "1: uncertainties each", fill: "#7b3f00"},
{source: "1: uncertainties each", target: "1: could materially adversely affect", fill: "#7b3f00"},
{source: "1: could materially adversely affect", target: "1: financial condition cash", fill: "#7b3f00"},
{source: "1: financial condition cash", target: "1: operations", fill: "#7b3f00"},
{source: "1: certain risks", target: "6: adversely affected", fill: "#cd9575"},
{source: "6: adversely affected", target: "6: by such risks then", fill: "#cd9575"},
{source: "6: by such risks then", target: "6: trading price", fill: "#cd9575"},
{source: "6: trading price", target: "6: common stock could decline", fill: "#cd9575"},
{source: "6: common stock could decline", target: "6: could lose", fill: "#cd9575"},
{source: "6: could lose", target: "6: investment", fill: "#cd9575"},
{source: "6: adversely affected", target: "9: market price", fill: "#d0f0c0"},
{source: "9: market price", target: "9: drug delivery pharmaceutical", fill: "#d0f0c0"},
{source: "9: drug delivery pharmaceutical", target: "9: biotechnology medical", fill: "#d0f0c0"},
{source: "9: biotechnology medical", target: "9: high technology companies", fill: "#d0f0c0"},
{source: "9: high technology companies", target: "9: highly volatile", fill: "#d0f0c0"},
{source: "9: market price", target: "14: significant", fill: "#ff1dce"},
{source: "14: significant", target: "14: fluctuations", fill: "#ff1dce"},
{source: "14: fluctuations", target: "14: volatility", fill: "#ff1dce"},
{source: "14: volatility", target: "14: expectations", fill: "#ff1dce"},
{source: "14: expectations", target: "14: announcement", fill: "#ff1dce"},
{source: "14: announcement", target: "14: exploration", fill: "#ff1dce"},
{source: "14: exploration", target: "14: strategic alternatives", fill: "#ff1dce"},
{source: "14: strategic alternatives", target: "14: entry into", fill: "#ff1dce"},
{source: "14: entry into", target: "14: discontinuance", fill: "#ff1dce"},
{source: "14: discontinuance", target: "14: collaborative", fill: "#ff1dce"},
{source: "14: collaborative", target: "14: relationship", fill: "#ff1dce"},
{source: "14: relationship", target: "14: announcements by us", fill: "#ff1dce"},
{source: "14: announcements by us", target: "14: competitors", fill: "#ff1dce"},
{source: "14: competitors", target: "14: technological", fill: "#ff1dce"},
{source: "14: technological", target: "14: innovations clinical trial", fill: "#ff1dce"},
{source: "14: innovations clinical trial", target: "14: new product development initiatives", fill: "#ff1dce"},
{source: "14: new product development initiatives", target: "14: new commercial product introductions", fill: "#ff1dce"},
{source: "14: new commercial product introductions", target: "14: regulatory developments", fill: "#ff1dce"},
{source: "14: regulatory developments", target: "14: of the United Sates ", fill: "#ff1dce"},
{source: "14: of the United Sates ", target: "14: developments", fill: "#ff1dce"},
{source: "14: developments", target: "14: current structure", fill: "#ff1dce"},
{source: "14: current structure", target: "14: health care financing", fill: "#ff1dce"},
{source: "14: health care financing", target: "14: payment systems", fill: "#ff1dce"},
{source: "14: payment systems", target: "14: proprietary rights", fill: "#ff1dce"},
{source: "14: proprietary rights", target: "14: commencement", fill: "#ff1dce"},
{source: "14: commencement", target: "14: litigation", fill: "#ff1dce"},
{source: "14: litigation", target: "14: general market", fill: "#ff1dce"},
{source: "14: general market", target: "14: economic conditions", fill: "#ff1dce"},
{source: "14: significant", target: "19: sustain profitability will depend on", fill: "#ff003f"},
{source: "19: sustain profitability will depend on", target: "19: successfully", fill: "#ff003f"},
{source: "19: successfully", target: "19: acceptance", fill: "#ff003f"},
{source: "19: acceptance", target: "19: existing products", fill: "#ff003f"},
{source: "19: existing products", target: "19: development", fill: "#ff003f"},
{source: "19: development", target: "19: regulatory approvals", fill: "#ff003f"},
{source: "19: regulatory approvals", target: "19: successfully manufacture", fill: "#ff003f"},
{source: "19: successfully manufacture", target: "19: market new", fill: "#ff003f"},
{source: "19: market new", target: "19: new product introductions", fill: "#ff003f"},
{source: "19: new product introductions", target: "19: competitors", fill: "#ff003f"},
{source: "19: competitors", target: "19: efficiently manage", fill: "#ff003f"},
{source: "19: efficiently manage", target: "19: resolve current", fill: "#ff003f"},
{source: "19: resolve current", target: "19: litigation matters", fill: "#ff003f"},
{source: "19: sustain profitability will depend on", target: "43: competitors", fill: "#faebd7"},
{source: "43: competitors", target: "43: private corporations", fill: "#faebd7"},
{source: "43: private corporations", target: "43: academic institutions governmental agencies", fill: "#faebd7"},
{source: "43: academic institutions governmental agencies", target: "43: private research", fill: "#faebd7"},
{source: "43: private research", target: "43: organizations", fill: "#faebd7"},
{source: "43: organizations", target: "43: manufacturing", fill: "#faebd7"},
{source: "43: manufacturing", target: "43: iontophoretic", fill: "#faebd7"},
{source: "43: iontophoretic", target: "43: drug delivery systems", fill: "#faebd7"},
{source: "43: competitors", target: "58: agreement", fill: "#d71868"},
{source: "58: agreement", target: "58: party contains terms", fill: "#d71868"},
{source: "58: party contains terms", target: "58: takeover attempts", fill: "#d71868"},
{source: "58: takeover attempts", target: "58: opportunity", fill: "#d71868"},
{source: "58: opportunity", target: "58: shareholders", fill: "#d71868"},
{source: "58: agreement", target: "95: timeconsuming", fill: "#0ff"},
{source: "95: timeconsuming", target: "95: costly product", fill: "#0ff"},
{source: "95: costly product", target: "95: development activities", fill: "#0ff"},
{source: "95: development activities", target: "95: clinical trials", fill: "#0ff"},
{source: "95: clinical trials", target: "95: seek regulatory", fill: "#0ff"},
{source: "95: seek regulatory", target: "95: new applications", fill: "#0ff"},
{source: "95: timeconsuming", target: "START_HERE", fill: "#0ff"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Oil and Gas Exploration and Production</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price">Price</a></td>
      <td>A prince is a male ruler (ranked below a king, grand prince, and grand duke) or a male member of a monarch's or former monarch's family. Prince is also a title of nobility (often highest), often hereditary, in some European states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_power">Market power</a></td>
      <td>In economics, market power refers to the ability of a firm to influence the price at which it sells a product or service by manipulating either the supply or demand of the product or service to increase economic profit. In other words, market power occurs if a firm does not face a perfectly elastic demand curve and can set its price (P) above marginal cost (MC) without losing revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_discrimination">Price discrimination</a></td>
      <td>Price discrimination is a microeconomic pricing strategy where identical or largely similar goods or services are sold at different prices by the same provider in different markets. Price discrimination is distinguished from product differentiation by the more substantial difference in production cost for the differently priced products involved in the latter strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Volatility_(finance)">Volatility (finance)</a></td>
      <td>In finance, volatility (usually denoted by σ) is the degree of variation of a trading price series over time, usually measured by the standard deviation of logarithmic returns.\nHistoric volatility measures a time series of past market prices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Share_price">Share price</a></td>
      <td>A share price is the price of a single share of a number of saleable equity shares of a company.\nIn layman's terms, the stock price is the highest amount someone is willing to pay for the stock, or the lowest amount that it can be bought for.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_Fund">Collaborative Fund</a></td>
      <td>Collaborative Fund is a venture capital firm focused on providing seed and early stage funding to technology companies.\n\n\n== Firm ==\nFounded in 2010 by Craig Shapiro, the firm is based in New York City, New York, and manages approximately $250 million of investor capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grove_Collaborative">Grove Collaborative</a></td>
      <td>Grove Collaborative is a benefit corporation headquartered in San Francisco. The company is an e-commerce retailer that sells natural household and personal care beauty products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_journalism">Collaborative journalism</a></td>
      <td>Collaborative journalism is a growing practice in the field of journalism. One definition is "a cooperative arrangement (formal or informal) between two or more news and information organizations, which aims to supplement each organization’s resources and maximize the impact of the content produced." It is practiced by both professional and amateur reporters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IOMED INC      Item 1A                                  RISK FACTORS       Our business is subject to <font color="blue">certain risks</font> and <font color="blue">uncertainties</font>, each of which     <font color="blue">could materially <font color="blue">adversely</font> affect</font> our business, <font color="blue">financial condition</font>, cash     flows  and  results  of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider the     <font color="blue"><font color="blue">following risks</font> prior</font> to investing in us</td>
    </tr>
    <tr>
      <td>You <font color="blue">should also</font> keep in mind that     the <font color="blue">following risks</font> are not the only risks we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks we are unaware of or risks that we currently     believe are not material <font color="blue">also may impair us</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue"><font color="blue">adversely</font> affected</font>     by such risks, then the <font color="blue">trading price</font> of our <font color="blue">common stock could decline</font>, and     you <font color="blue">could lose</font> all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should also</font> refer to the     other information set forth in this <font color="blue">Annual Report </font>on Form 10-K, including     the <font color="blue">discussions set forth</font> in “Business” and “Management’s Discussion and     Analysis of Financial Condition and Results of Operations” as well as our     <font color="blue">financial statements</font> and the related notes</td>
    </tr>
    <tr>
      <td>The  <font color="blue">market price</font> for the securities of <font color="blue">drug delivery</font>, <font color="blue">pharmaceutical</font>,     bio<font color="blue">technology</font>, medical device and other <font color="blue">high <font color="blue">technology</font> companies</font> has been     <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has <font color="blue"><font color="blue">significant</font>ly affected</font> the market     prices  for  these  securities for <font color="blue">reasons frequently unrelated</font> to the     operating  performance  of  the  <font color="blue">specific company</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font>     <font color="blue"><font color="blue">fluctuations</font> may <font color="blue">adversely</font> affect</font> the <font color="blue">market price</font> of our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common shares</font> has fluctuated <font color="blue">significant</font>ly since     <font color="blue">public trading commenced</font> and it is likely that it <font color="blue">will continue</font> to fluctuate     in future</td>
    </tr>
    <tr>
      <td>Events and factors that may have a     <font color="blue">significant</font> impact on our business and on the <font color="blue">market price</font> of our common     shares include the following:       ·                  <font color="blue">fluctuations</font> or <font color="blue">volatility</font> in operating results compared     to market <font color="blue">expectations</font>;       ·                  <font color="blue">announcement</font> of the outcome, if any, of our <font color="blue">exploration</font>     of <font color="blue">strategic <font color="blue">alternative</font>s</font>;       ·                  our <font color="blue">entry into</font> or <font color="blue">discontinuance</font> of a <font color="blue">collaborative</font>     <font color="blue">relationship</font>;       ·                  <font color="blue">announcement</font>s by us or our <font color="blue"><font color="blue">competitor</font>s</font> of <font color="blue">technological</font>     innovations, clinical trial results, <font color="blue">new product <font color="blue">development</font> initiatives</font>, or     <font color="blue">new commercial product introductions</font>;       ·                  <font color="blue"><font color="blue">regulatory</font> <font color="blue"><font color="blue">development</font>s</font></font> in the United Sates or foreign     countries;       ·                  changes in the <font color="blue">current structure</font> of <font color="blue">health care financing</font>     and <font color="blue">payment systems</font>;       ·                  <font color="blue"><font color="blue">development</font>s</font> in or disputes regarding patent or other     <font color="blue"><font color="blue">proprietary</font> rights</font>;       ·                  <font color="blue">commencement</font> or the results of any <font color="blue">litigation</font>; and       ·                  <font color="blue">general market</font> and <font color="blue">economic conditions</font></td>
    </tr>
    <tr>
      <td>These and other <font color="blue">factors may</font> cause the <font color="blue">market price</font> and demand for our common     stock to fluctuate <font color="blue">substantially</font>, which may limit or <font color="blue">prevent investors from</font>     readily  selling our <font color="blue">common shares</font> and <font color="blue">otherwise negatively</font> effect the     liquidity for our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>In addition, sales of substantial amounts     of our <font color="blue">common shares</font>, including <font color="blue">shares issued upon</font> the exercise of stock     options, could <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">sales <font color="blue">could also</font></font> make it more <font color="blue">difficult</font> for us to <font color="blue">sell equity securities</font> or     equity-related securities in the future at a time and price that we deem     <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">sustain profitability</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">sustain profitability</font> will <font color="blue">depend on</font> a number of factors     including:       ·                  our ability to maintain and <font color="blue">successfully</font> expand market     <font color="blue">acceptance</font> and sales of <font color="blue">existing products</font>;       ·                  our ability to <font color="blue">successfully</font> complete the <font color="blue">development</font> of,     receive <font color="blue"><font color="blue">regulatory</font> approvals</font> for and <font color="blue">successfully</font> <font color="blue">manufacture</font> and <font color="blue">market new</font>     products;       ·                  the nature and timing of any <font color="blue">new product introductions</font>     relative to our <font color="blue"><font color="blue">competitor</font>s</font>; and       ·                  our ability to <font color="blue">efficiently manage</font> and <font color="blue">resolve current</font>     <font color="blue">litigation</font> matters</td>
    </tr>
    <tr>
      <td>With limited exception, prior to fiscal 2003, we <font color="blue">sustained losses</font> in each     <font color="blue">fiscal year</font></td>
    </tr>
    <tr>
      <td>We had an <font color="blue">accumulated deficit</font> of dlra31dtta1 million as of June 30,     2006</td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________       We rely on a limited number of <font color="blue"><font color="blue">in<font color="blue">dependent</font> third</font> <font color="blue">party <font color="blue">distributors</font></font></font> to sell     our products, one of <font color="blue">whom recently terminated</font> their <font color="blue">distribution <font color="blue">agreement</font></font>     with us</td>
    </tr>
    <tr>
      <td>We market our products through a <font color="blue">nationwide network</font> of <font color="blue">in<font color="blue">dependent</font> third</font>     <font color="blue">party <font color="blue">distributors</font></font> and <font color="blue">manufacturing</font> sales representatives, which provide us     indirect  access to the <font color="blue">clinicians</font> that use our products to <font color="blue">administer</font>     <font color="blue">patient <font color="blue">treatments</font></font></td>
    </tr>
    <tr>
      <td>Limited access to end <font color="blue">user customers may</font> result in     <font color="blue">reduced <font color="blue">future sales</font></font> and <font color="blue">market penetration</font> of current and <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Our sales growth is <font color="blue"><font color="blue">dependent</font> on</font> our ability to <font color="blue">broaden distribution</font> and     <font color="blue">market penetration</font> of our current and <font color="blue">future products</font>, which may require an     expanded  marketing  presence  through  direct  sales and marketing or     co-marketing of products with <font color="blue">collaborative</font> partners or <font color="blue">distributors</font> that     have national or market-specific marketing capabilities</td>
    </tr>
    <tr>
      <td>We may not be able     to maintain existing, or establish new, marketing <font color="blue"><font color="blue">arrangement</font>s</font> on favorable     terms, if at all</td>
    </tr>
    <tr>
      <td>Two <font color="blue">distributors</font> combined to account for approximately 43prca, 40prca and 32prca of     our <font color="blue">total <font color="blue">product sales</font></font> for the <font color="blue">fiscal year</font>s ended June 30, 2006, 2005 and     2004</td>
    </tr>
    <tr>
      <td>One  of  these  <font color="blue">distributors</font>,  Compex  Technologies  (formerly     Rehabilicare, Inc</td>
    </tr>
    <tr>
      <td>) was our <font color="blue">second largest distributor</font> and accounted for     over 16prca of our <font color="blue">total <font color="blue">product sales</font></font> during each of the <font color="blue">past three fiscal</font>     years</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>their <font color="blue"><font color="blue">acquisition</font> by</font> Encore Medical Corporation, the     parent company of our primary <font color="blue">competitor</font> (Empi, Inc</td>
    </tr>
    <tr>
      <td>), Compex elected to     terminate its <font color="blue">distribution <font color="blue">agreement</font></font> with us <font color="blue">effective</font> July 1, 2006</td>
    </tr>
    <tr>
      <td>The     loss of this <font color="blue">distributor will</font> have a negative effect on our <font color="blue">future sales</font> and     operating results</td>
    </tr>
    <tr>
      <td>Demand for our products is <font color="blue"><font color="blue">dependent</font> on</font> third party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">sales depend</font>, in part, on continued <font color="blue">reimbursement</font> by third party     payers to <font color="blue">clinicians</font> and their patients for using our products in patient     <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>These  third  party  payers, including <font color="blue"><font color="blue">government</font> health</font>     administration authorities, private health insurers and other <font color="blue">organizations</font>,     can affect the pricing and <font color="blue">relative attractiveness</font> of using our products and     competing  products,  including  <font color="blue">alternative</font>  therapies, by regulating     <font color="blue">reimbursement</font> levels</td>
    </tr>
    <tr>
      <td>Changes in these relative <font color="blue">reimbursement</font> levels may     affect  sales of our product</td>
    </tr>
    <tr>
      <td>In addition, some of these <font color="blue">payers limit</font>     <font color="blue">reimbursement</font> amounts paid to <font color="blue">health care providers</font> for use of our products     in <font color="blue">certain <font color="blue">application</font>s</font> and may further limit <font color="blue">reimbursement</font> in the future</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">significant</font> uncertainty exists as to the <font color="blue">reimbursement</font> status     of any new product we may develop</td>
    </tr>
    <tr>
      <td>The business in which we operate is <font color="blue">intensely competitive</font> and prone to rapid     <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>Our  commercial  business  has  formidable  <font color="blue">competition</font>, and we expect     <font color="blue">competition</font> to remain intense during fiscal 2007 and beyond</td>
    </tr>
    <tr>
      <td>Our <font color="blue">technology</font>     <font color="blue">competes with various companies</font> in the <font color="blue">drug delivery</font>, <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">industries</font> are <font color="blue">highly competitive</font> and     rapidly evolving with <font color="blue">significant</font> <font color="blue"><font color="blue">development</font>s</font> expected to <font color="blue">continue at</font> a     rapid pace</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> include public and <font color="blue">private corporations</font>,     academic institutions, <font color="blue">government</font>al agencies and public and <font color="blue">private research</font>     <font color="blue">organizations</font> that are involved in developing, <font color="blue">manufacturing</font> or marketing     <font color="blue">iontophoretic</font> and other <font color="blue">drug <font color="blue">delivery systems</font></font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font> are     <font color="blue">substantially</font> larger with greater financial and other resources, have more     experience, have greater name recognition, offer broader product lines, and     are able to <font color="blue">offer discounts as</font> a <font color="blue">competitive tactic</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> may     succeed in more rapidly developing <font color="blue">competing <font color="blue">technologies</font></font>, obtaining FDA     approval, or <font color="blue">gaining market</font> share for <font color="blue">products than us</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue"><font color="blue">competitor</font>s</font>     currently have <font color="blue"><font color="blue">drug delivery</font> products approved</font> or in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Some of     these products could be more <font color="blue">effective</font> or <font color="blue">commercially</font> attractive to our     customers than our products</td>
    </tr>
    <tr>
      <td>In the case of <font color="blue">new products</font>, the first product to reach the market is often     able to establish and maintain <font color="blue">significant</font> market share relative to later     entrants to the market</td>
    </tr>
    <tr>
      <td>New drugs or further <font color="blue">development</font> of <font color="blue">alternative</font>     drug  delivery  <font color="blue"><font color="blue">methods may</font> provide greater therapeutic benefits</font> for a     <font color="blue">specific drug</font> or <font color="blue">indication</font> or <font color="blue">may offer comparable performance at lower</font>     costs than our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font>’ ability to more rapidly develop     new <font color="blue">products than us</font> represents a <font color="blue">significant</font> competitive advantage</td>
    </tr>
    <tr>
      <td>No  <font color="blue"><font color="blue">transaction</font> may</font> result from our <font color="blue">determination</font> to <font color="blue">explore strategic</font>     <font color="blue">alternative</font>s</td>
    </tr>
    <tr>
      <td>We  commenced a process in <font color="blue">September </font>2005 to <font color="blue">explore various strategic</font>     <font color="blue">alternative</font>s to seek to <font color="blue">maximize shareholder value</font>, including <font color="blue">possible sale</font>     <font color="blue"><font color="blue">transaction</font>s involving</font> our <font color="blue">entire company</font> or certain of our assets</td>
    </tr>
    <tr>
      <td>We are     <font color="blue">uncertain whether</font> any <font color="blue"><font color="blue">transaction</font> will</font> result from this process</td>
    </tr>
    <tr>
      <td>If a     <font color="blue">transaction</font> does result, we are uncertain what its form or terms would be</td>
    </tr>
    <tr>
      <td>Any <font color="blue">transaction</font> that does result from this <font color="blue">process may</font> not       15     ______________________________________________________________________       ultimately <font color="blue">maximize shareholder value</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">transaction</font> does not result     from that process our stock price may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties     </font>and adverse effects related to this process include:       ·                  <font color="blue">disruption</font> of <font color="blue">operations</font> and <font color="blue">distraction</font> of <font color="blue">management</font>’s     attention;       ·                  perceived <font color="blue">uncertainties</font> regarding our future direction     resulting in the loss of and increasing the <font color="blue">difficult</font>y of <font color="blue">attracting new</font>     customers, employees or business partners;       ·                  <font color="blue">difficult</font>ies retaining or <font color="blue">replacing key employees</font>;       ·                  the incurrence of costs and expense related to this     process; and       ·                   <font color="blue">inability</font> to identify and consummate an attractive     strategic <font color="blue">alternative</font></td>
    </tr>
    <tr>
      <td>A material <font color="blue">agreement</font> to which we are a <font color="blue">party contains terms</font> that may deter     <font color="blue">takeover attempts</font> and limit the <font color="blue">opportunity</font> of our <font color="blue">shareholders</font> to sell     their shares at a favorable price</td>
    </tr>
    <tr>
      <td>We are party to a cross-license <font color="blue">agreement</font> with <font color="blue">Alza Corporation </font>pursuant to     which  we have exchanged non-exclusive, royalty free rights to certain     patented  <font color="blue">technologies</font>  <font color="blue">which each party</font> believed to be of <font color="blue">significant</font>     strategic  importance  to  the potential <font color="blue">technological</font> success of many     <font color="blue">iontophoretic</font> <font color="blue">drug delivery</font> <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>This <font color="blue">agreement</font> may have the     effect of delaying or preventing the sale, merger, assignment, or transfer     of  all  or  part of our company or <font color="blue">technologies</font> because both Alza and     ourselves  are prohibited from assigning rights under the <font color="blue">agreement</font> to     certain named companies or to any other entity that derives more than 50     percent of its <font color="blue">income from</font> the <font color="blue">development</font>, licensing and/or sale of drug     <font color="blue">delivery systems</font> to other <font color="blue"><font color="blue">pharmaceutical</font> companies without</font> the consent of     the other party</td>
    </tr>
    <tr>
      <td>In addition, this <font color="blue">agreement</font> may limit our ability to     <font color="blue">capitalize</font>  on  the  commercial  and  other  <font color="blue">economic potential</font> of our     <font color="blue">technologies</font> through <font color="blue">collaborative</font> and other <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">utilize net</font> operating <font color="blue">losses may become</font> limited and <font color="blue">adversely</font>     <font color="blue">affect financial</font> results</td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we had approximately dlra20 million and dlra15 million in     federal and state net operating loss carryforwards, respectively</td>
    </tr>
    <tr>
      <td>Our     ability  to  utilize  these  net operating <font color="blue">loss carryforwards could</font> be     <font color="blue">significant</font>ly limited if we or our <font color="blue">shareholders</font> engage in <font color="blue">transaction</font>s that     result in an “ownership change” as defined in Section 382 of the Internal     Revenue Code</td>
    </tr>
    <tr>
      <td>If our usage of net operating losses were to become subject     to <font color="blue">limitation</font> and if at that time we are profitable, our earnings and cash     <font color="blue">flows could</font> be <font color="blue">adversely</font> impacted due to our <font color="blue">increased tax <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">financial benefits</font> of certain <font color="blue">strategic <font color="blue">alternative</font>s</font>, which     may be available to us, such as a <font color="blue">disposition</font> of a portion of our assets,     would  be reduced if the use of our net operating losses is subject to     <font color="blue">limitation</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">relies on</font> our <font color="blue">proprietary</font> <font color="blue">technology</font> and <font color="blue">intellectual property</font>     rights</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our and our <font color="blue">licensors</font>’ <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We     rely on a <font color="blue">combination</font> of patents, trade secrets, <font color="blue">confidential</font>ity procedures,     trademarks, licensing <font color="blue"><font color="blue">arrangement</font>s</font> and <font color="blue">copyrights</font> to establish and protect     our <font color="blue"><font color="blue">proprietary</font> rights</font> position</td>
    </tr>
    <tr>
      <td>The creation and protection of <font color="blue">proprietary</font>     rights is expensive and may require us to engage in costly and <font color="blue">distracting</font>     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Despite these <font color="blue">efforts third parties could copy</font> or <font color="blue">otherwise use</font>     our <font color="blue">technology</font> without authorization</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">drug delivery</font>, <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     companies  are  <font color="blue">highly uncertain</font> and <font color="blue">involve complex legal</font> and factual     questions</td>
    </tr>
    <tr>
      <td>The patents owned and licensed by us may not prevent other     <font color="blue">companies from</font> developing similar or <font color="blue">therapeutically equivalent products</font> and     <font color="blue">licensors</font> who have licensed <font color="blue">technology</font> to us on a non-exclusive basis may     license the same <font color="blue">technology</font> to <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, other companies     may be <font color="blue">issued patents</font> that prevent the sale of our products or require     licensing and the payment of <font color="blue">significant</font> royalties by us</td>
    </tr>
    <tr>
      <td>Any current or     <font color="blue">new products</font>, processes, or <font color="blue">methods may</font> not be patentable or may not provide     an <font color="blue">exclusive position</font> in the covered subject matter</td>
    </tr>
    <tr>
      <td>Furthermore, our     <font color="blue">pending patent <font color="blue">application</font>s may</font> not result in <font color="blue">issued patents</font>, we or our     <font color="blue">licensors</font> may not protect <font color="blue">issued patents</font>, we <font color="blue">may become involved</font> in patent     <font color="blue">infringement</font>  actions,  and  our and our licensor’s patents may not be     enforceable or may not <font color="blue">provide meaningful protection</font></td>
    </tr>
    <tr>
      <td>We also operate in     many <font color="blue">foreign countries</font> that do not protect <font color="blue">intellectual property</font> rights to     the <font color="blue">same extent as</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on trade secrets</font> and other <font color="blue">confidential</font> <font color="blue">proprietary</font> information     which  we  seek  to  protect  through <font color="blue">confidential</font>ity <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">competitor</font>s</font>  may  in<font color="blue">dependent</font>ly  develop similar information and these     <font color="blue">agreement</font>s may not be <font color="blue">effective</font> to <font color="blue">prevent <font color="blue">disclosure</font></font> of our <font color="blue">confidential</font>     information or <font color="blue">provide adequate remedy</font> in the event of an <font color="blue">unauthorized</font>     <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">competitor</font>s</font> gain access to our <font color="blue">proprietary</font>       16     ______________________________________________________________________       <font color="blue">technology</font> or information, our business, <font color="blue">financial position</font>, and results of     <font color="blue">operations</font> may be materially <font color="blue">adversely</font> impacted</td>
    </tr>
    <tr>
      <td><font color="blue">Third Parties </font>claiming that we infringe their <font color="blue"><font color="blue">proprietary</font> rights</font> <font color="blue">regardless</font>     of  their <font color="blue">merit could</font> cause us to incur <font color="blue">significant</font> legal expenses and     <font color="blue">prevent us from selling</font> our products</td>
    </tr>
    <tr>
      <td>From  time to time, we have received claims that we have infringed the     <font color="blue">intellectual property</font> rights of others and lawsuits alleging such have been     <font color="blue">brought against us</font>, including <font color="blue">one such lawsuit</font> that is <font color="blue">currently pending</font>     (EEMSO, Inc</td>
    </tr>
    <tr>
      <td>Compex Technologies, Inc</td>
    </tr>
    <tr>
      <td>These claims have included <font color="blue"><font color="blue">allegation</font>s</font> of <font color="blue">infringement</font> of     patents, trade secrets, or other <font color="blue"><font color="blue">proprietary</font> rights</font> as well as <font color="blue"><font color="blue">allegation</font>s</font>     of  unfair  <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>For example, the claim <font color="blue">brought against us</font> by     Travanti  Pharma  was  <font color="blue">resolved through</font> a settlement that included the     <font color="blue">acquisition</font> of certain <font color="blue">intellectual property</font> rights for dlra750cmam000 after we     had incurred <font color="blue">significant</font> fees and expenses in the defense of that matter</td>
    </tr>
    <tr>
      <td>The  ultimate  outcome  of any <font color="blue">allegation</font> or lawsuit is uncertain and,     <font color="blue">regardless</font> of outcome, any such claim, with or without merit, could be time     consuming to defend, result in costly <font color="blue">litigation</font>, and divert <font color="blue">management</font>’s     time and <font color="blue">attention from</font> our business</td>
    </tr>
    <tr>
      <td>A claim <font color="blue">successfully</font> brought could     result in us being required to stop selling, delay shipping, or <font color="blue">redesign one</font>     or more of our products</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">could also</font> be required to satisfy     <font color="blue">indemnification obligations</font> to some of our customers, purchase a license to     use the <font color="blue">intellectual property</font>, and pay substantial <font color="blue">monetary damages</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">development</font> is expensive, time consuming, and may be <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>We are required to undertake time-consuming and <font color="blue">costly product</font>     <font color="blue">development</font> <font color="blue">activities</font>, including <font color="blue">clinical trials</font>, and <font color="blue">seek <font color="blue">regulatory</font></font>     approval  for  <font color="blue">new <font color="blue">application</font>s</font> and products</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font>     efforts, either alone or in <font color="blue">collaboration with</font> other parties, may never be     <font color="blue">successfully</font> completed, obtain <font color="blue"><font color="blue">regulatory</font> approvals</font>, be <font color="blue"><font color="blue">manufacture</font>d at</font>     acceptable cost or with <font color="blue">appropriate</font> quality, meet market needs or achieve     market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Before <font color="blue">seeking <font color="blue">regulatory</font> approval</font> of our products, we     may not <font color="blue">successfully</font> complete <font color="blue">preclinical studies</font> or <font color="blue">clinical trials</font> that     <font color="blue">demonstrate</font> our products are both safe and <font color="blue">effective</font> for use in the target     <font color="blue">indication</font>s</td>
    </tr>
    <tr>
      <td>The results of preclinical and early <font color="blue">clinical trials</font> are not     <font color="blue">indicative</font> of the results of large <font color="blue">scale testing</font></td>
    </tr>
    <tr>
      <td>A new product <font color="blue">could also</font>     produce undesirable side effects that could result in the <font color="blue">interruption</font>,     delay or suspension of <font color="blue">clinical trials</font>, or the failure to obtain FDA or     other <font color="blue">regulatory</font> approval for targeted <font color="blue">indication</font>s</td>
    </tr>
    <tr>
      <td>If our <font color="blue">future products</font> are not shown to be safe and <font color="blue">effective</font> in clinical     trials,  resulting delays in developing other compounds and conducting     related <font color="blue">preclinical testing</font> and <font color="blue">clinical trials</font>, as well as the need for     <font color="blue"><font color="blue">additional</font> financing</font> to complete <font color="blue">such testing</font> and trials, could have a     material adverse effect on our business, <font color="blue">financial condition</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Product revenues on <font color="blue">future products</font> may not be realized for     <font color="blue">several years</font>, and, if our product <font color="blue">development</font> efforts are <font color="blue">unsuccessful</font>, may     never be achieved</td>
    </tr>
    <tr>
      <td>Even if a product <font color="blue">development</font> effort is successful, a     product  could  prove  to  be  <font color="blue">difficult</font>  to  <font color="blue">commercialize</font> because of     <font color="blue">manufacturing</font> costs or lack of market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>We may need to raise     <font color="blue"><font color="blue">additional</font> capital</font> or <font color="blue">enter into</font> a <font color="blue">collaborative</font> <font color="blue">arrangement</font> in order to     undertake a <font color="blue">significant</font> new product <font color="blue">development</font> effort</td>
    </tr>
    <tr>
      <td>If  we are unable to maintain <font color="blue">relationship</font>s with current <font color="blue">collaborative</font>     partners or <font color="blue">enter into</font> new <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> then our business     could be harmed</td>
    </tr>
    <tr>
      <td>Part of our business strategy is to form <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> with     corporate  partners,  <font color="blue">licensors</font>,  licensees  and other parties for the     <font color="blue">development</font>, clinical testing, <font color="blue">manufacture</font>, marketing or <font color="blue">commercialization</font>     of our products or products in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The process of <font color="blue">establishing</font> a     <font color="blue">collaborative</font>  <font color="blue">arrangement</font>  is <font color="blue">difficult</font>, time-consuming, and involves     <font color="blue">significant</font> uncertainty</td>
    </tr>
    <tr>
      <td><font color="blue">Discussions </font><font color="blue">with potential collaborators may</font> not     lead to the <font color="blue">establishment</font> of a successful <font color="blue">collaborative</font> <font color="blue">relationship</font> with     favorable terms</td>
    </tr>
    <tr>
      <td>Once established, a <font color="blue">collaborative</font> <font color="blue">arrangement</font> may prove to     be <font color="blue">unsuccessful</font> or may not generate <font color="blue">significant</font> revenue</td>
    </tr>
    <tr>
      <td>Until we enter     into  <font color="blue">additional</font>  <font color="blue">collaborative</font>  <font color="blue"><font color="blue">arrangement</font>s</font>,  we will be required to     <font color="blue">internally</font>  fund  all  research  and <font color="blue">development</font> expenditures</td>
    </tr>
    <tr>
      <td><font color="blue">Future     </font><font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> may require that we continue to fund all or a     portion of product <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td><font color="blue">Collaborative </font><font color="blue"><font color="blue">arrangement</font>s</font> limit our <font color="blue">flexibility</font> in pursuing <font color="blue">alternative</font>s     for the <font color="blue">development</font> or <font color="blue">commercialization</font> of products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategic partner</font>     may not <font color="blue">comply with</font> the terms of the <font color="blue">agreement</font>, elect       17     ______________________________________________________________________       not to <font color="blue">provide funding</font>, or terminate the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">strategic partner</font> may     also pursue <font color="blue">alternative</font> competitive <font color="blue">products on</font> its own or <font color="blue">with others</font>,     including our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>If we are unable to establish, and to the extent we choose to defer the     <font color="blue">establishment</font>  of,  <font color="blue">collaborative</font>  <font color="blue"><font color="blue">arrangement</font>s</font>,  we  will  experience     <font color="blue">significant</font>ly increased business risk and <font color="blue">capital <font color="blue">requirements</font> with respect</font>     to any <font color="blue">significant</font> new product <font color="blue">development</font> we choose to undertake</td>
    </tr>
    <tr>
      <td>We could     also encounter <font color="blue">significant</font> delays in bringing any resulting products to     market  or find that the <font color="blue">development</font>, <font color="blue">manufacture</font> or sale of resulting     products is <font color="blue"><font color="blue">adversely</font> affected</font> by the absence of <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font></td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key personnel</font> could <font color="blue">adversely</font> impact our business</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on</font> the <font color="blue">continued services</font> of our <font color="blue">key personnel</font> that have     acquired <font color="blue">specialized knowledge</font> and <font color="blue">skills with respect</font> to our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The loss of one or more of these <font color="blue">key personnel</font> could negatively impact our     performance</td>
    </tr>
    <tr>
      <td>In addition, were we to have to <font color="blue">replace one</font> or more of these     individuals or were to seek to hire <font color="blue">additional</font> personnel we would experience     the intense <font color="blue">competition</font> that exists in our industry for the limited number     of <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">effective</font>ly manage expanded <font color="blue">operations</font> for existing or     <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Expanded  </font>business  <font color="blue">operations</font>  could  result  in  new  and  increased     <font color="blue">responsibilities</font> for our <font color="blue">management</font> personnel and place <font color="blue">significant</font> strain     on our <font color="blue">management</font>, operating and <font color="blue">financial systems</font> and other resources</td>
    </tr>
    <tr>
      <td>To     <font color="blue">accommodate</font> any <font color="blue">such expansion</font> and compete <font color="blue">effective</font>ly, we may be required     to implement improved information systems, procedures and controls, and to     hire <font color="blue">additional</font> personnel which we may not be able to do <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a limited number of suppliers</td>
    </tr>
    <tr>
      <td>Key <font color="blue">materials used</font> in many of our <font color="blue">electrode products</font> have limited sources of     supply</td>
    </tr>
    <tr>
      <td>Although we believe that, if necessary, <font color="blue">alternative</font> sources could     be  developed and/or alternate materials substituted for each of these     limited <font color="blue">source materials</font>, this <font color="blue">activity could</font> result in <font color="blue">interruption</font>s in our     business and <font color="blue">manufacturing</font> <font color="blue">operations</font>, increased costs and time for product     <font color="blue"><font color="blue">validation</font>s</font>, and <font color="blue">additional</font> <font color="blue">regulatory</font> submissions and approvals</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">production <font color="blue">capacity</font></font> and <font color="blue">manufacturing</font> experience and rely on     <font color="blue">contract <font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>Our Phoresor <font color="blue">dose <font color="blue">controller</font>s</font> and <font color="blue">certain patch components</font> are <font color="blue">manufacture</font>d     under  contracts with third party <font color="blue">manufacture</font>rs and we <font color="blue">rely on them</font> to     <font color="blue">manufacture</font> a <font color="blue">sufficient quantity</font> of product to <font color="blue">satisfy demand</font> for our     <font color="blue">products on</font> a <font color="blue">timely basis</font> and to <font color="blue">meet quality</font> and <font color="blue">performance standards</font> for     the  <font color="blue">manufacturing</font>  <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In  the  event of a loss of a contract     <font color="blue">manufacture</font>r, we would be required to identify, qualify, and validate an     <font color="blue">alternative</font> supply source within a <font color="blue">reasonable period</font> of time</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> all of our <font color="blue">iontophoretic</font> <font color="blue">drug delivery</font> electrode patches in     quantities  sufficient  to satisfy our <font color="blue">current level</font> of <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Significant </font> </font><font color="blue">capital expenditures</font> for <font color="blue">manufacturing</font> equipment or a new     contract <font color="blue">manufacturing</font> <font color="blue">relationship</font> may be required to <font color="blue">increase <font color="blue">capacity</font></font> for     existing  products  or  any  <font color="blue"><font color="blue">modification</font>s</font> to <font color="blue">existing products</font> or new     products</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font> <font color="blue">increase <font color="blue">capacity</font></font> on a     <font color="blue">profitable basis</font>, or <font color="blue">contract with</font> another party on acceptable terms, if at     all</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>increases in <font color="blue">production volume could likely</font> require changes in     products  and <font color="blue">manufacturing</font> processes in order to <font color="blue">facilitate increased</font>     <font color="blue">production automation</font> and our efforts to <font color="blue">automate production may</font> not be     successful</td>
    </tr>
    <tr>
      <td>Accordingly, we may not be able to <font color="blue">successfully</font> increase     <font color="blue">production on</font> a <font color="blue">profitable basis</font> or at all</td>
    </tr>
    <tr>
      <td>Our and our third party <font color="blue">manufacture</font>r’s <font color="blue">facilities</font> operate in <font color="blue">accordance</font> with     the FDA’s Quality System Regulations and other <font color="blue">quality systems <font color="blue">regulations</font></font>,     including  ISO13485,  which is similar to ISO 9001 but with <font color="blue">additional</font>     elements  <font color="blue">specifically</font>  for  medical device <font color="blue">manufacture</font>rs, and <font color="blue">CE Mark     </font>standards</td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">also audited by</font> the FDA for <font color="blue">compliance with</font> good     <font color="blue">manufacturing</font> process (GMP) <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure by us</font> or our contract     <font color="blue">manufacture</font>r to maintain <font color="blue">compliance with</font> any of these <font color="blue">regulations</font> could have     a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, the research, <font color="blue">development</font>, <font color="blue">manufacture</font> and marketing     of our products is regulated by the FDA, which requires approval of drugs     and <font color="blue">medical devices</font> before they can be marketed</td>
    </tr>
    <tr>
      <td>Similar approvals are also     required  from other <font color="blue">regulatory</font> bodies outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">regulatory</font> processes established by these <font color="blue"><font color="blue">government</font> agencies</font> are extensive     and uncertain, and compliance is expensive</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">approval may</font> be     withdrawn and the applicable <font color="blue">regulations</font> may change</td>
    </tr>
    <tr>
      <td>Even  if we obtain and maintain <font color="blue">regulatory</font> approval for a product, the     <font color="blue">manufacture</font> of it and related <font color="blue">operations</font> are subject to extensive <font color="blue">government</font>     regulation and <font color="blue">periodic inspections</font> to confirm <font color="blue">compliance with</font> procedures     relative  to  control and <font color="blue">documentation</font> of product design, control and     <font color="blue">validation</font>  of  the <font color="blue">manufacturing</font> process and <font color="blue">overall product quality</font></td>
    </tr>
    <tr>
      <td><font color="blue">Discovery </font>of a failure to <font color="blue">comply with</font> applicable <font color="blue">regulations</font> could result in     FDA or other <font color="blue">regulatory</font> sanctions, restrictions, or an order to withdraw     and/or recall a product</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">currently allows us</font> to market our <font color="blue">iontophoretic</font> <font color="blue">dose <font color="blue">controller</font>s</font> and     <font color="blue">electrode products</font> for <font color="blue">use with ions</font> of <font color="blue">soluble salts</font> or other <font color="blue">drugs under</font>     the FDA’s 510(k) <font color="blue">regulations</font> governing <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>We also have FDA     approval to market Iontocaine, our own brand of lidocaine, for use with our     Phoresor <font color="blue">system but stopped marketing</font> <font color="blue">Iontocaine </font>in fiscal 2005</td>
    </tr>
    <tr>
      <td>In 1994,     the  FDA  publicly  stated that it intends to require <font color="blue">manufacture</font>rs of     <font color="blue">iontophoretic</font> devices to obtain Pre-Market Approval (PMA) for marketed     devices currently used with drugs not <font color="blue">specifically</font> labeled for <font color="blue">iontophoretic</font>     delivery, which would include our dose <font color="blue">controller</font> for <font color="blue">use with ions</font> of     <font color="blue">soluble salts</font> or other drugs, such as <font color="blue">dexamethasone</font></td>
    </tr>
    <tr>
      <td>The agency to date has     not <font color="blue">published such</font> a regulation</td>
    </tr>
    <tr>
      <td>If  the  FDA requires a PMA for our <font color="blue">iontophoretic</font> devices, we would be     required to seek FDA approval to continue to market those devices</td>
    </tr>
    <tr>
      <td>Such a     regulation could require that an <font color="blue">application</font> be filed as quickly as 90 days     after the <font color="blue">publication</font> date of the regulation</td>
    </tr>
    <tr>
      <td>In such an event we might not     be able to complete and file a PMA within the prescribed time period, or the     FDA  might  not  <font color="blue">provide approval</font></td>
    </tr>
    <tr>
      <td>Failure to submit a PMA within the     prescribed time period and ultimately to obtain FDA <font color="blue">approval could</font> result in     our being required to <font color="blue">cease commercial distribution</font> of the Phoresor system     for <font color="blue">use with <font color="blue">dexamethasone</font></font> or any other drug other than Iontocaine</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">interference with</font> our ability to distribute our Phoresor system for use with     <font color="blue">dexamethasone</font>  would  have  a material adverse effect on our financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">iontophoretic</font> dose <font color="blue">controller</font> and <font color="blue">electrode kits</font> are <font color="blue">marketed under</font>     510(k)  clearance</td>
    </tr>
    <tr>
      <td>Since  obtaining  these  <font color="blue">clearances</font>  we have made     <font color="blue"><font color="blue">modification</font>s</font> to <font color="blue">certain products</font></td>
    </tr>
    <tr>
      <td>Under the FDA’s <font color="blue">regulations</font>, we are     required to obtain an <font color="blue">additional</font> 510(k) clearance if we modify a device for     which  we  have  <font color="blue">previously</font>  received a 510(k) clearance in a way that     <font color="blue">significant</font>ly  affects the safety or efficacy of the device, or if the     <font color="blue">modification</font>  results in a major change in <font color="blue">intended use</font></td>
    </tr>
    <tr>
      <td>Based on the     limited <font color="blue">guidance provided by</font> the FDA to assist <font color="blue">manufacture</font>rs in determining     whether  they are required to obtain a 510(k) clearance for a modified     device, we determined that a new 510(k) submission was not required in     connection with <font color="blue">certain products</font></td>
    </tr>
    <tr>
      <td>However, the FDA could require us to     obtain one or more <font color="blue">additional</font> 510(k) <font color="blue">clearances</font> in the future for certain of     those products</td>
    </tr>
    <tr>
      <td>During that process, we could be <font color="blue">prohibited from marketing</font>     the modified device until the clearance is obtained from the FDA       We may require <font color="blue"><font color="blue">additional</font> capital</font> in the future and that <font color="blue">capital may</font> not be     available</td>
    </tr>
    <tr>
      <td>Our future capital <font color="blue">requirements</font> <font color="blue">depend on</font> many factors, including:       ·                  the costs, timing, and success of our product <font color="blue">development</font>     <font color="blue">activities</font>, including <font color="blue">preclinical studies</font> and <font color="blue">clinical trials</font> and the terms     of any associated <font color="blue">collaborative</font> <font color="blue">relationship</font>;       ·                  <font color="blue">market demand</font> for any new product resulting from our     product <font color="blue">development</font> activity;       ·                   <font color="blue">requirements</font>  to improve or increase <font color="blue">manufacturing</font>     <font color="blue">capacity</font>;       ·                  the costs, timing, and success of our sales and marketing     efforts       ·                  <font color="blue">acquisition</font> opportunities;       ·                  the terms of any new <font color="blue">collaborative</font> <font color="blue">relationship</font>s;       ·                  competing <font color="blue">technological</font> and market <font color="blue"><font color="blue">development</font>s</font>; and       ·                   the  costs  to obtain, maintain and to enforce our     <font color="blue">intellectual property</font> rights and <font color="blue">defend ourselves from</font> claims that we have     infringed a third party’s <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       Although we believe that at current operating levels, existing cash balances     and cash generated from <font color="blue">operations</font> will be sufficient to fund our operating     needs through fiscal 2008 and beyond; we may be required or elect to raise     <font color="blue"><font color="blue">additional</font> capital</font> before that time</td>
    </tr>
    <tr>
      <td>To satisfy capital <font color="blue">requirements</font>, we     may seek to <font color="blue">raise funds through public</font> or private financings, <font color="blue">collaborative</font>     <font color="blue">relationship</font>s or other <font color="blue"><font color="blue">arrangement</font>s</font> that may be dilutive to <font color="blue">shareholders</font>,     involve <font color="blue">significant</font> restrictive covenants, or require us to <font color="blue">relinquish</font>     rights  to  certain  <font color="blue">technologies</font>,  products or <font color="blue">marketing territories</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>capital, if required, may not be <font color="blue">available on terms</font> satisfactory     to  us,  if at all</td>
    </tr>
    <tr>
      <td>Failure to raise capital when needed could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisition  </font>activity  could  disrupt our ongoing business and involve     <font color="blue">significant</font> risks</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions  </font>are  <font color="blue">inherently</font>  risky</td>
    </tr>
    <tr>
      <td>We  can not be certain that an     <font color="blue">acquisition</font> will be successful and will not materially <font color="blue">adversely</font> affect our     business</td>
    </tr>
    <tr>
      <td>We have acquired and in the <font color="blue">future may evaluate</font> and acquire     businesses, services, products or <font color="blue">technologies</font> that <font color="blue">compliment</font> our strategic     direction</td>
    </tr>
    <tr>
      <td>These <font color="blue">acquisition</font>s may involve <font color="blue">significant</font> risks, including:       ·                  <font color="blue">potentially dilutive issuances</font> of our stock;       ·                  incurrence of debt and <font color="blue">contingent <font color="blue">liabilities</font></font>;       ·                   <font color="blue">inability</font>  to  <font color="blue">successfully</font> integrate the acquired     <font color="blue">technologies</font>, services, products, and <font color="blue">operations</font> into our business and to     maintain uniform standards, controls, policies and procedures;       ·                   <font color="blue">distraction</font>  of  <font color="blue">management</font>  from  normal business     <font color="blue">operations</font>;       ·                  insufficient <font color="blue">revenue generation</font> to <font color="blue">offset <font color="blue">liabilities</font></font>     assumed and justify the <font color="blue">purchase price</font>;       ·                  write offs related to <font color="blue">intangible assets</font>; and       ·                  <font color="blue">unidentified issues</font> not discovered in the due diligence     process</td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">liability</font> insurance</font> is costly and <font color="blue">difficult</font> to obtain</td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">liability</font> insurance</font> in our industry is expensive and <font color="blue">difficult</font> to     obtain and we may not be able to maintain <font color="blue">existing levels</font> of coverage or     obtain desired <font color="blue">coverage on</font> acceptable terms in the future</td>
    </tr>
    <tr>
      <td>In addition, we     are not sure if our <font color="blue">existing coverage</font> is adequate</td>
    </tr>
    <tr>
      <td>An <font color="blue">inability</font> to maintain     or obtain sufficient product <font color="blue"><font color="blue">liability</font> insurance</font> on acceptable terms to     <font color="blue">protect against potential <font color="blue">product <font color="blue">liability</font></font></font> claims <font color="blue">could prevent</font> or inhibit     the continued <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>If we were <font color="blue">successfully</font> sued for <font color="blue">product <font color="blue">liability</font></font> we could face substantial     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Our  business  <font color="blue">exposes us</font> to <font color="blue">potential <font color="blue">liability</font> risks inherent</font> in the     testing, marketing and sale of <font color="blue">drug delivery</font> and related <font color="blue">pharmaceutical</font>     products for use in humans, including <font color="blue">product <font color="blue">liability</font></font> claims, product     recall, or <font color="blue">excessive warranty</font> claims</td>
    </tr>
    <tr>
      <td>The use of our products in clinical     trials and the sale of <font color="blue">future products</font> may also expose us to potential     <font color="blue">product <font color="blue">liability</font></font> risks</td>
    </tr>
    <tr>
      <td>A successful <font color="blue">product <font color="blue">liability</font></font> claim in excess of     our <font color="blue">insurance coverage could</font> have a material adverse effect on our business     and <font color="blue">could further prevent us from</font> obtaining product <font color="blue"><font color="blue">liability</font> insurance</font> in     the future on <font color="blue">commercially</font> desirable or <font color="blue">reasonable terms</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">involves environmental risks</font> that may result in <font color="blue">liability</font> for     us</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of     hazardous materials, chemicals and <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td>The use,     disposal  and handling of these materials are <font color="blue">extensively regulated by</font>     federal, state and local <font color="blue">government</font> authorities</td>
    </tr>
    <tr>
      <td>Although we believe our     <font color="blue">safety procedures</font> for handling and disposing of <font color="blue">such materials comply</font> in all     material  respects  with the <font color="blue">standards prescribed by</font> state and federal     <font color="blue">regulations</font>, the risk of <font color="blue"><font color="blue">accident</font>al environmental contamination</font> or personal     <font color="blue">injury from</font> these <font color="blue">materials cannot</font> be <font color="blue">completely eliminated</font> and we could be     required to incur <font color="blue">significant</font> costs to <font color="blue">comply with</font> applicable <font color="blue">regulations</font> in     the future</td>
    </tr>
    <tr>
      <td>Furthermore, in the event of an <font color="blue">accident</font>, we could be held     liable for any damages and any such <font color="blue">liability</font> could exceed our resources</td>
    </tr>
  </tbody>
</table>